Elucidation of molecular mechanism of drug resistance acquisition targeting cancer stem cells of gastric cancer and development of novel treatment
| Project/Area Number |
17K16561
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2017-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | CD44v9 / 癌幹細胞 / 胃癌 / 5-FU / 薬剤感受性 / 活性酸素 / 化学療法感受性 / がん幹細胞 / 抗癌剤耐性 |
|---|
| Outline of Final Research Achievements |
Gastric cancer patients with CD44v9 high expression (57 cases) showed significantly worse prognosis compared to those with low expression patients (147 cases) (overall survival p=0.001, progression free survival p=0.001). CD44v9 high expression group also showed significantly lower histological therapeutic response compared to low expression group (p=0.025). Knockdown of CD44v9 in gastric cancer cell lines with CD44v9 high expression (MKN45 and NUGC4) increased drug sensitivity to 5-FU with decrease of GSH level and increase of ROS level.
|
| Academic Significance and Societal Importance of the Research Achievements |
CD44v9発現は癌の浸潤・転移に関わるだけでなく、薬剤の組織学的治療効果と有意に相関していた。細胞株の実験において、CD44v9は細胞内のROSを制御することによって、5-FUの薬剤感受性に影響を与えている可能性がある。以上より、胃癌におけるCD44v9発現は化学療法感受性バイオマーカーとなりうる可能性が示唆された。
|
Report
(3 results)
Research Products
(3 results)
